 |
|
|
| |
No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg-Chronic Hepatitis B Virus Infection
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
P Marcellin1, EJ Heathcote2, A Corsa3, Y Liu3,
MD Miller3, and KM Kitrinos3
1Hepatology Department, HopitalBeaujon, University of Paris, Clichy, France;
2Toronto General Hospital, University of Toronto, Ontario, Canada;
3Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
